Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$21.10 USD

21.10
1,979,088

-0.03 (-0.14%)

Updated Sep 16, 2025 03:59 PM ET

After-Market: $21.50 +0.40 (1.90%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medtronic (MDT) Introduces New Drug Coated Balloon Catheter

by Zacks Equity Research

Medtronic's (MDT) newly-launched Prevail DCB demonstrates impressive safety and drug deliverability, utilizing a rapid absorption drug to treat patients with coronary artery disease.

Zacks Equity Research

Omnicell (OMCL) Faces Lingering Cost Woes, Fierce Competition

by Zacks Equity Research

Omnicell's (OMCL) second-quarter 2021 guidance includes additional freight costs, given the ongoing global market conditions.

Zacks Equity Research

NuVasive (NUVA) Launches Modulus ALIF for Anterior Spine Surgery

by Zacks Equity Research

The Modulus ALIF 3D-printed porous titanium implant is the latest addition to NuVasive's (NUVA) AMS portfolio for anterior lumbar interbody fusion procedures.

Zacks Equity Research

Medtronic's (MDT) Hugo RAS System Now Available at UC CHRISTUS

by Zacks Equity Research

Recent integration of Medtronic's (MDT) Hugo RAS System at UC CHRISTUS is intended to support the teaching institution's new robotic surgery program.

Zacks Equity Research

Quest Diagnostics (DGX) Expands Testing Access With CLX Pact

by Zacks Equity Research

Quest Diagnostics' (DGX) COVID-19 testing will be available through TrustAssure platform for international travelers and live event attendants.

Zacks Equity Research

NVST vs. PETQ: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NVST vs. PETQ: Which Stock Is the Better Value Option?

Zacks Equity Research

Cerner (CERN) Extends Partnership to Accelerate Digital Health

by Zacks Equity Research

Cerner (CERN) expands its partnership with Baystate Health by launching a digital health platform to boost consumer-focused care.

Zacks Equity Research

Integra (IART) Releases Favorable PriMatrix Clinical Outcome

by Zacks Equity Research

Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.

Zacks Equity Research

Thermo Fisher (TMO) Advances Customer Research With New Launch

by Zacks Equity Research

Thermo Fisher's (TMO) new instrument enables high-resolution images of nanoparticles and beam-sensitive materials to be obtained from a commercially available desktop SEM.

Zacks Equity Research

Globus Medical (GMED) Marks New Milestone for ExcelsiusGPS

by Zacks Equity Research

Globus Medical's (GMED) ExcelsiusGPS Robotic Navigation system reaches new surgical milestone for spinal procedures.

Zacks Equity Research

Thermo Fisher (TMO) to Meet Plasmid DNA Demand With New Facility

by Zacks Equity Research

Thermo Fisher's (TMO) new facility will manufacture materials that are essential for production of plasmid-based therapies and vaccines.

Zacks Equity Research

National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes

by Zacks Equity Research

National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.

Zacks Equity Research

Integra's (IART) SurgiMend Gets Innovative Technology Contract

by Zacks Equity Research

Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.

Zacks Equity Research

Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System

by Zacks Equity Research

Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.

Zacks Equity Research

Here's Why You Should Retain Avanos (AVNS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Zacks Equity Research

Hologic (HOLX) COVID Test With Saliva Sample Gets CE Mark

by Zacks Equity Research

Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.

Zacks Equity Research

Orthofix's (OFIX) SpinalStim Demonstrates Improved Fusion Rates

by Zacks Equity Research

Orthofix's (OFIX) SpinalStim bone growth device demonstrates impressive fusion rates for patients recovering from lumbar fusion surgery.

Zacks Equity Research

Stryker (SYK) Unveils Tornier Shoulder Arthroplasty Portfolio

by Zacks Equity Research

Stryker (SYK) introduces new Tornier shoulder arthroplasty portfolio enabling the company to strengthen its position in the shoulder market.

Zacks Equity Research

Here's Why You Should Retain Change Healthcare (CHNG) Stock

by Zacks Equity Research

Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.

Zacks Equity Research

Thermo Fisher's (TMO) New Pact Drives Sustainable Lab Practices

by Zacks Equity Research

Thermo Fisher (TMO) expects to ACT label more than 1,200 additional SKUs to allow research, pharmaceutical and clinical laboratories to achieve their sustainability objectives.

Zacks Equity Research

QIAGEN (QGEN) Stock Falls on Downbeat Full-Year Guidance

by Zacks Equity Research

According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.

Zacks Equity Research

NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes

by Zacks Equity Research

We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.

Zacks Equity Research

Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about Hill-Rom (HRC) on robust international growth and raised 2021 outlook.

Zacks Equity Research

Medtronic (MDT) Reports Economic Findings on PRODIGY Data

by Zacks Equity Research

Medtronic (MDT)-sponsored PRODIGY Trial data was used to analyze cost benefits and outcomes from continuous pulse oximetry and capnography monitoring in high-risk patients.

Zacks Equity Research

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.